Steven Idell Selected Research

Collagen

2/2024	Myocardin regulates fibronectin expression and secretion from human pleural mesothelial cells.
4/2022	Myo5b Transports Fibronectin-Containing Vesicles and Facilitates FN1 Secretion from Human Pleural Mesothelial Cells.
1/2022	DOCK2 Promotes Pleural Fibrosis by Modulating Mesothelial to Mesenchymal Transition.
1/2017	KIF5A transports collagen vesicles of myofibroblasts during pleural fibrosis.
4/2015	Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs.
2/2012	Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steven Idell Research Topics

Disease

20	Fibrosis (Cirrhosis) 02/2024 - 04/2003
19	Inflammation (Inflammations) 08/2023 - 01/2002
18	Lung Injury 01/2022 - 05/2003
15	Pulmonary Fibrosis (Fibrosing Alveolitis) 08/2023 - 04/2003
14	Empyema 05/2023 - 11/2004
14	Infections 01/2023 - 02/2009
14	Acute Lung Injury 08/2018 - 01/2002
9	Pneumonia (Pneumonitis) 08/2023 - 08/2002
9	Neoplasms (Cancer) 12/2015 - 08/2002
6	Sepsis (Septicemia) 05/2017 - 01/2002
5	Hemorrhage 01/2021 - 04/2015
4	Pleural Effusion (Pleural Effusions) 02/2021 - 02/2012
4	Wounds and Injuries (Trauma) 01/2020 - 05/2003
4	Malignant Mesothelioma 07/2013 - 06/2010
4	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 12/2012 - 01/2002
4	Carcinoma (Carcinomatosis) 07/2008 - 07/2004
3	Lung Diseases (Lung Disease) 08/2023 - 04/2015
3	Chronic Obstructive Pulmonary Disease (COPD) 08/2023 - 01/2014
3	Idiopathic Pulmonary Fibrosis 01/2022 - 01/2014
3	Pleurisy (Pleuritis) 01/2021 - 10/2002
3	Edema (Dropsy) 07/2011 - 01/2006
2	Cicatrix (Scar) 01/2023 - 01/2022
2	Dyspnea (Shortness of Breath) 01/2021 - 09/2020
2	COVID-19 01/2021 - 09/2020
2	Thrombosis (Thrombus) 07/2013 - 03/2006
2	Mesothelioma 07/2013 - 09/2010
2	Human Influenza (Influenza) 01/2012 - 07/2011
2	Weight Loss (Weight Reduction) 01/2012 - 07/2011
2	Interstitial Lung Diseases (Interstitial Lung Disease) 12/2008 - 01/2004
2	Hepatocellular Carcinoma (Hepatoma) 05/2007 - 01/2007
2	Renal Insufficiency (Renal Failure) 01/2006 - 05/2003
2	Pulmonary Edema 06/2003 - 05/2003
1	Atherosclerosis 10/2023
1	Disease Progression 08/2023
1	Pulmonary Arterial Hypertension 08/2023
1	Asthma (Bronchial Asthma) 08/2023
1	Obesity 01/2022
1	Mycobacterium avium-intracellulare Infection 01/2022

Drug/Important Bio-Agent (IBA)

20	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 02/2021 - 10/2002
19	FibrinIBA 01/2022 - 01/2002
17	Proteins (Proteins, Gene)FDA Link 02/2024 - 07/2004
16	Plasminogen Activator Inhibitor 1IBA 05/2023 - 05/2003
11	Plasminogen Activators (Plasminogen Activator)IBA 02/2021 - 04/2003
10	Bleomycin (Blenoxane)FDA LinkGeneric 01/2024 - 07/2013
7	CytokinesIBA 12/2022 - 06/2003
7	Biomarkers (Surrogate Marker)IBA 02/2021 - 03/2011
7	Messenger RNA (mRNA)IBA 07/2013 - 01/2004
6	CollagenIBA 02/2024 - 02/2012
6	SmokeIBA 08/2018 - 05/2007
5	SootIBA 01/2024 - 02/2014
5	Phosphotransferases (Kinase)IBA 01/2021 - 01/2014
5	Thromboplastin (Tissue Factor)IBA 02/2016 - 05/2003
5	Peptide Hydrolases (Proteases)FDA Link 06/2015 - 08/2002
4	Peptides (Polypeptides)IBA 05/2023 - 02/2018
4	AnticoagulantsIBA 06/2018 - 01/2002
4	Urokinase Plasminogen Activator ReceptorsIBA 06/2010 - 05/2003
3	Transcription Factors (Transcription Factor)IBA 04/2024 - 12/2015
3	Tissue Plasminogen Activator (Alteplase)FDA Link 05/2023 - 06/2018
3	caveolin-1 (82-101)IBA 03/2022 - 01/2015
3	AntigensIBA 01/2022 - 01/2012
3	Fibrinolysin FDA Link 01/2021 - 05/2003
3	Thrombin FDA Link 01/2021 - 03/2006
3	fibrin fragment D (D-dimer)IBA 01/2021 - 10/2009
3	Protein CIBA 01/2017 - 05/2002
3	Tetracycline (Achromycin)FDA LinkGeneric 04/2015 - 10/2002
3	Carrier Proteins (Binding Protein)IBA 07/2008 - 01/2004
2	Fibronectins (Fibronectin)IBA 02/2024 - 04/2022
2	CalponinsIBA 01/2022 - 01/2019
2	indium-bleomycinIBA 01/2022 - 12/2019
2	Oxygen (Dioxygen)IBA 10/2021 - 01/2019
2	BilirubinIBA 01/2021 - 09/2020
2	activated protein C receptorIBA 01/2021 - 07/2013
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 09/2020
2	InterferonsIBA 01/2019 - 12/2016
2	Superoxides (Superoxide)IBA 01/2019 - 01/2016
2	EnzymesIBA 08/2018 - 01/2007
2	Surface-Active Agents (Surfactants)IBA 01/2017 - 12/2008
2	Anti-Bacterial Agents (Antibiotics)IBA 12/2016 - 01/2006
2	Double-Stranded RNA (RNA, Double Stranded)IBA 12/2016 - 12/2015
2	PlasminogenIBA 01/2016 - 05/2003
2	Factor X (Stuart Factor)IBA 02/2012 - 01/2006
2	Tyrosine (L-Tyrosine)FDA Link 03/2011 - 01/2004
2	monoamine-sulfating phenol sulfotransferaseIBA 03/2011 - 01/2007
2	3-nitrotyrosineIBA 03/2011 - 01/2007
2	Sulfates (Sulfates, Inorganic)IBA 05/2007 - 01/2007
2	Factor VIIa (Activated Factor VII)IBA 01/2006 - 05/2003
2	AsbestosIBA 11/2004 - 01/2004
1	LDL Receptors (LDL Receptor)IBA 10/2023
1	Mechanistic Target of Rapamycin Complex 2IBA 08/2023
1	Immunologic Factors (Immunomodulators)IBA 12/2022
1	Interleukin-1 (Interleukin 1)IBA 12/2022
1	FructoseIBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	Matrix Metalloproteinases (MMPs)IBA 01/2022
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022
1	Immune Checkpoint ProteinsIBA 01/2022

Therapy/Procedure

9	Therapeutics 01/2022 - 05/2003
7	Thrombolytic Therapy 05/2023 - 06/2013
2	Contraindications 05/2023 - 01/2021
2	Pleurodesis 07/2008 - 03/2006